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Introduction
Gestational trophoblastic disease (GTD) consists of a spectrum 
of disorders that range from premalignant molar pregnancies to 
malignant tumours. Gestational trophoblastic neoplasm (GTN) 
is the result of a malignant transformation of placental villous 
and extravillous trophoblasts and it is important to remember 
that these lesions arise from foetal and not maternal tissue. 
After evacuation, trophoblastic tissue can persist in 20% of 
patients. GTN can arise from a normal or abnormal pregnancy 
and includes persistent or invasive mole (75%), choriocarcinoma 
(25%) and the rare placental site trophoblastic tumour (PSTT) and 
epithelioid trophoblastic tumour (ETT). The WHO-classification 
also includes an unclassified trophoblastic tumour category.1-6
The incidence of GTN differs amongst countries around the 
world with reported high incidence in South-East Asia of 
15–19/1000 births, while a low incidence is observed in the 
Western World with 0.12–0.7/1000 births. Risk factors for GTN 
include a prior molar pregnancy, advance maternal age (> 40yrs), 
Asian and American-Indian ancestry, theca lutein cysts larger 
than 6 cm, excessive uterine growth, and a pre-evacuation 
human chorionic gonadotropin (hCG) level of more than 
100 000 IU/L. GTN have an excellent prognosis with prompt 
diagnosis and appropriate therapy.2,3,6
Although human immunodeficiency virus (HIV) is not an 
apparent risk factor for GTN, HIV patients tend to present with 
advanced GTN disease, and have a significantly worse prognosis. 
Globally 51% of people living with HIV (PLWH) are female and 
AIDS-related illnesses are still the leading cause of death among 
women of reproductive age between 15–49 years. Sub-Saharan 
Africa represents 64% of the global HIV-burden and Eastern 
and Southern Africa reported an estimated 19.4 million cases. 
Globally, 17% of the world population is currently living with 
HIV/AIDS with 750 000 newly infected adults and children, and 
420 000 deaths due to AIDS related disease. In 2016, for the first 
time, deaths from AIDS-related illnesses declined 27% among 
women and young girls according to the 2017 UNAIDS Data 
report.7 
Since the introduction of antiretroviral therapy (ART) an increase 
in non-AIDS (NAIDS) malignancies is observed with an incidence 
of 30–40% among PLWH, and since 2010, NAIDS malignancy has 
outnumbered AIDS-defining cancers. Factors that contribute to 
NAIDS malignancy include the lack of autoimmune surveillance, 
the imbalance that exists between cellular differentiation and 
proliferation, and the repeated antigen stimulation that lead to 
proliferation of abnormal cells. Patients present at a younger age 
with atypical presentations, and metastatic disease that is more 
aggressive in behavior.8,9 
PLWH live longer due to antiretroviral therapy (ART) and develop 
cancers relating to HIV and ageing. The disparity in cancer care 
is large and significant, and PLWH are 2–3 times more likely to 
receive no cancer treatment compared to uninfected people. This 
might be due to a lack of management guidelines, the potential 
for drug interactions, overlapping toxicities between cancer 
drugs and ART that might further enhance immunosuppression, 
with an increased risk of infectious compilations. In PLWH, 
routine screening is less frequent than in the general population. 
Clinicians should be vigilant to symptoms suggestive of early 
malignant disease and help patients to minimize risk factors for 
cancer: smoking cessation programs, HPV vaccines, HBV vaccine 
and the treatment of hepatitis B and hepatitis C infection. PLWH 
are generally poor surgical candidates with an increased risk of 
postoperative infections.10 More PLWH and cancer should receive 
appropriate cancer treatment.
The 2017 World Health Organization (WHO) global report on HIV/AIDS estimated that sub-Saharan Africa comprised 64% of 
the global HIV burden, with a current estimate of 19.4 million cases in Eastern and Southern Africa. Since the introduction of 
antiretroviral therapy (ART) there has been a 30–40% increase in the incidence of non-AIDS malignancies. Gestational trophoblastic 
disease comprises of a spectrum of pregnancy-related disorders with an overall cure rate of 90%. The response to treatment is 
generally favourable but the associated complications of HIV, comorbidities, poor performance status and extent of metastatic 
disease in gestational trophoblastic neoplasm patients receiving chemotherapy, compromises the outcome and survival.
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PLWH also experience a higher cancer-specific mortality 
independent of cancer stage or cancer treatment and 
immunosuppression may play a role in the increased cancer-
specific mortality that supports the rationale for early initiation 
of ART. In a retrospective review of 1.8 million patients with a 
cohort of 6500 HIV-positive patients, a significant cancer-specific 
morality was observed for colorectal, lung, melanoma and breast 
cancers.11,12,13 
Diagnosis and staging of GTN 1,2,4-6
The criteria for GTN diagnosis include any of the following:
• 4 or more human chorionic gonadotrophin (hCG) levels that 
plateau over 3 weeks
• 10% hCG increase in more than 3 levels over a 2-week period
• Histological confirmation of choriocarcinoma
• hCG > 20 000 IU/L 4 weeks post-evacuation
• Post-evacuation bleeding that is not due to retained tissue
• Detectable hCG levels 6 months post-evacuation of a molar 
pregnancy
Once the diagnosis for a GTN is established, evaluation for systemic 
disease is pursued. Staging investigations include a chest X-ray, 
transvaginal sonar, abdomen-pelvis computer tomography (CT) 
and, if vaginal and/or lung metastases is present, a brain CT or a 
magnetic resonance image (MRI) is recommended (Table 1). The 
role of positron emission tomography (PET) in staging of GTN is 
unclear but may be useful in detecting resistant disease sites or 
lesions for possible resection. 
Patients are staged according to the International Federation 
of Gynecology and Obstetrics (FIGO) classification and then 
allocated a WHO risk-score. 
Table 2: Figo staging for GTN1-6
FIGO Stage Description
I Tumours strictly confined to the uterus corpus
II Tumours extending to the adnexae or vagina, but 
limited to the genital structures
III Tumours extending to the lungs, with or without 
genital tract involvement
IV All other metastatic sites
Table 3: WHO scoring system based on prognostic factors1-6
Risk factor 0 1 2 4




Interval from index 
pregnancy, months








Largest tumour size 
including uterus, cm
- 3–4 ≥ 5 -








- 1–4 5–8 > 8
Previous failed 
chemotherapy




The risk-category helps to guide management with either 
single agent or combination chemotherapy. A WHO risk-score 
of ≤ 6 is regarded low-risk and patients are managed with 
single agent chemotherapy. A score of ≥ 7 constitutes high-risk 
and it is unlikely that this group of patients will be cured with 
a single agent; therefore, combination chemotherapy is the 
recommended standard. A grey-zone exists around a count of 
5–6 and/or a clinicopathological diagnosis of choriocarcinoma; 
single agent therapy might cure some but careful follow-up is 





• Discrete round nodules
• Snowstorm pattern
• Pleural effusion
• Pulmonary Arterial occlusion
80%
CT Abdomen-pelvis Liver, Kidney, GIT, Spleen 10%
Pelvic Sonar Vagina, lower genital tract 30%
MRI or CT Brain 10%








Nephrotic syndrome  [PSTT or ETT]
If hCG > 100 000 IU/mL  [Thyroid storm]
PET Identify potentially resectable lesions
CXR: Chest X-Ray; CT: Computer Tomography; MRI: Magnetic Resonance Imaging; PET: Positron Emission Tomography; hCG: human chorionic gonadotrophin; HIV Eliza 
test; VL: Viral Load
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necessary, as 50–60% of these patients will require second-line 
chemotherapy for cure.1-6  
Ultra-high-risk disease includes extensive liver, lung or brain 
metastases, a FIGO score of more than 12, major bleeding, 
and a hCG level in excess of 1 000 000IU/L. Early deaths occur 
within 4 weeks of treatment and are mostly due to respiratory 
compromise because of haemorrhage within the thorax, 
intraperitoneal or intracranial spaces, and secondary to the 
tumour burden and resultant rapid tumour destruction that 
occurs with chemotherapy. Hence the introduction with low-
dose therapy (LD) that gradually reduces tumour volume and 
associated tumour oedema. The LD-EP regime, consisting of 
Etoposide 100 mg/m² and Cisplatin 20 mg/m² intravenously 
on days 1 and 2, given weekly till patients are clinically stable, 
has increased the already good overall survival by a further 




The risk-category helps to guide management with either single agent or combination chemotherapy. 
A WHO i -score of ≤ 6 i  regarded low-risk and p tients are managed with single agent 
chemotherapy. A score of ≥ 7 c nsti utes high-risk and it is unlikely that this group of patients will be 
cured with a single agent; therefore, combination ch motherapy is the recommended standard. A grey-
zone exists around a cou t of 5–6 and/or a clinic pathological diagnosis of choriocarcinoma; single 
agent therapy might cure some but careful follow-up is necessary, as 50–60% of these patients will 
require second-line chemothera y for cure.1-6   
Ultra-high-risk disease includes extensive liver, lung or brain metastases, a FIGO score of more than 12, 
major bleeding, and a hCG level in excess of 1 000 000IU/L. Early deaths occur within 4 weeks of 
treatment and are mostly due to respiratory compromise because of haemorrhage within the thorax, 
intraperitoneal or intracranial spaces, and secondary to the tumour burden and resultant rapid tumour 
destruction that occurs with chemotherapy. Hence the introduction with low-dose therapy (LD) that 
gradually reduces tumour volume and associated tumour oedema. The LD-EP regime, consisting of 
Etoposide 100 mg/m² and Cisplatin 20 mg/m² intravenously on days 1 and 2, given weekly till patients 
are clinically stable, has increased the already good overall survival by a further 9% by preventing early 
deaths that occur with life threatening disease.1,2,4,14  
 
Management  
The diagnosis and management of GTN in PLWH requires a multidisciplinary team that includes the 
gynaecologist (suction curettage, and/or total abdominal hysterectomy), an HIV clinician, oncologist, 
chemotherapy nurse, social worker and auxiliary services. Pharmacists, oncologists and HIV clinicians all 
need to review cancer treatment for possible drug-interactions and overlapping toxicities. 
Indication for chemotherapy 1,3,4-6 
Post-evacuation hCG After 4 weeks hCG level still > 20 000 IU/L 
hCG not falling after 4 months 
6 months even if hCG is still falling 
• Single Agent therapy
Low-risk ≤ 6




• Initial Low-dose therapy
Ultra-high-risk > 12
e ent 
The di sis t of GTN in PLWH requires a 
multidisciplinary team that includes the gynaecologist (suction 
cur ttage, nd/or total abdomin l hysterectomy), an HIV 
clinician, oncologist, chemotherapy nurse, social worker a d 
auxiliary services. Pharmacists, oncologists and HIV clinicians all 
need to review cancer treatment for possible drug-interactions 
and overl pping toxicities.
Indication for chemotherapy 1,3,4-6
Post-evacuation 
hCG
After 4 weeks hCG level still > 20 000 IU/L
hCG not falling after 4 months
6 months even if hCG is still falling
Metastases Liver, lung, vulva, vagina
Any other site
CXR Lesions > 2 cm
Bleeding Vaginal, GIT or Intraperitoneal 
Choriocarcinoma Present
The choice of chemotherapy depends on the FIGO-WHO 
Prognostic score and risk groups, disease stage, and previous 
drug exposure. Remission is regarded as 3 consecutive normal 
hCG levels over a 14 to 21 day period. A normal hCG level requires 
3 additional cycles of therapy – trials confirmed that 2 versus 3 
cycles of consolidation therapy showed a doubling in recurrence 
rate, thus 3 additional cycles is regarded standard of care. Low 
blood counts do not mandate to delay or reduce dose unless 
complications with febrile neutropenia or a significant clinical 
event occurs. Colony stimulating factors (GSF) as secondary 
prophylaxis with G-CSF on days 3–6 and 9–14 with the EMA/
CO regime help to maintain dose-dense therapy and prevent 
neutropenia. 
Treatment recommendation by stage
M: Methotrexate; A: Actinomycin; E: Etoposide; C: 
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III High EMA/CO EMA/EP
Surgery
79%





Literature search reveals single institute publications of case 
studies for GTN and PLWH. To date, there is no evidence that 
GTD is more prevelant in patients with HIV. As far back as 1996, 
Rolansky et al. observed gynaecological neoplasms in HIV-
positive patients were more resistant to chemotherapy and 
appeared to have a poorer prognosis.15 In a retrospective review 
by Moodley et al. 78 patients were diagnosed with GTD, with 
a HIV seroprevalance of 31%. Among the HIV-positive patients 
who received chemotherapy and demised, the cause of death 
included widespread disease, multiorgan failure, and toxicity 
due to chemotherapy. Their findings also highlight the poor 
outcome of PLWH with a CD4 count less than 200 cells/µL, poor 
chemotherapy tolerance or performance status that precluded 
the administration of chemotherapy.16 
Tayib et al. published a 10-year, single institute, retrospective 
review of 76 GTN patients with an 18.4% cohort that was living 
with HIV infection. They conclude that more advanced stage, HIV 
seropositivity and poor complaince with treatment also portend 
poorer outcomes in GTN patients.17 
In a 2002 published case presentation (Ashley) with a literature 
review, only four cases of PLWH and choriocarcinoma had been 
reported. Low CD4 counts in HIV infection lead to poor outcome 
despite chemotherapy treatment and immunodeficiency can 
influence the course of treatment and outcome of patients.18 
In an East African report, Olwang and colleagues argue that 
HIV infection may predispose patients to extensive metastatic 
choriocarcinoma and influence the course of treatment, and 
proposed that HIV infection be considered a poor prognostic risk 
for GTN.19 
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Real world challenges
In developing and middle-income countries, socio-economic 
issues play a major role in the management of HIV-positive 
women diagnosed with GTN. In many societies women are the 
sole breadwinner of households and loss of workdays due to 
treatment lead to loss of income and poor treatment compliance. 
Lack of transport and financial resources contribute to poor 
treatment compliance as many women rely on public transport 
for hospital visits to specialized treatment centres.
Bed availability in hospitals make continuous infusion regimes 
problematic and 5-day Methotrexate versus pulse Actinomycin; 
EMA/CO [Day 1, 2, and day 8] versus MAC [Day 1 - 5 every 
3 weeks] versus BEP [Day 1 - 5 every 3 weeks] offer alternative 
chemotherapy choices for the patient. The HIV burden in newly 
diagnosed patients with associated low CD4 counts versus 
patients who are established on ART and the potential drug 
interactions make for challenging treatment decisions. In HIV-
positive patients with poor CD4, little clarity is available whether 
ART should commence speedily and the administration of 
chemotherapy delayed until immune reconstitution occurs. 
HIV and associated co-infections, e.g. pulmonary tuberculosis, 
cytomegalovirus and hepatitis infections, remain a challenge in 
the clinic. 
PLWH generally present with advance stage presentations 
with multiple lung and brain metastases. Both HIV and 
GTN have haematological complications with the potential 
risk of secondary infections and associated morbidity and 
mortality. Immunosuppression and low CD4 counts with poor 
performance status predict a poor response and tolerability to 
chemotherapy. Response to GTN is generally favourable but in 
PLWH and immune suppression, outcome is compromised due 
to treatment delays, haematological toxicity and secondary 
infections that contribute to poor tolerability and response to 
treatment with a resultant poor prognosis.
Conclusion
PLWH should be offered the same cancer therapy as HIV-negative 
individuals and no cancer treatment modifications should 
be made solely on the basis of HIV status. Care should be co-
managed with both the oncologist and HIV specialist. Response 
to treatment for GTN is generally favourable; the overall cure 
rate for GTN is 90% but the sequalae of HIV, the resultant low 
CD4 counts, comorbidities, poor performance status and extend 
of metastatic disease in patients receiving chemotherapy, 
compromise prognosis and survival. 
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